Pariet was generally well tolerated during clinical trials. The observed undesirable effects have generally been mild/moderate and transient in nature.
In clinical trials, the most common adverse events (incidence ≥5%) were headache, diarrhea and nausea. Other adverse events (incidence <5% and ≥2%) were rhinitis, abdominal pain, asthenia, flatulence, pharyngitis, vomiting, nonspecific pain/back pain, dizziness, flu-like syndrome, infection, cough, constipation and insomnia. Further less frequent adverse events (incidence ≤1%) were rash, myalgia, chest pain, dry mouth, dyspepsia, nervousness, somnolence, bronchitis, sinusitis, chills, eructation, leg cramps, urinary tract infection, arthralgia and fever.
In isolated cases, anorexia, gastritis, weight gain, depression, pruritus, vision or taste disturbances, stomatitis, sweating, leukocytosis have been observed.
However, only headaches, diarrhea, abdominal pain, asthenia, flatulence, rash and dry mouth have been associated with the use of Pariet.
Clinically Significant (Analogous Compounds):
Shock: It has been reported that anaphylactic reaction or shock occurred rarely with analogous compounds (omeprazole and lansoprazole). If any abnormality is observed, Pariet should be discontinued and appropriate treatment should be given.
Hematology: It has been reported that pancytopenia, thrombocytopenia, agranulocytosis and hemolytic anemia occurred rarely and granulocytopenia and anemia occurred infrequently with omeprazole and lansoprazole. If any abnormality is observed, Pariet should be discontinued and appropriate treatment should be given.
Post-Marketing Experience: Erythema and rarely bullous reactions have been reported in patients treated with Pariet which have usually resolved after discontinuation of therapy. Thrombocytopenia, neutropenia and leukopenia have been reported rarely. There have been reports of increased hepatic enzymes.